AK HB216

Requires entities making gene therapy products available in Alaska to conspicuously label products with "Potential Gene Therapy Product" unless the product is commonly known to be gene therapy, and take reasonable steps to notify potential purchasers of the label.

Mandates that upon written request from an Alaska resident, entities producing, selling, or distributing products with capacity to expose individuals to genetically modified material must provide all information including relevant reports, research, and knowledge about indirect exposure pathways, except proprietary or intellectual property-protected information.

Requires informed consent from all individuals who could be exposed to a product that could transmit to or be absorbed into them in ways resulting in genetic modification, and prohibits making such products available in the state if informed consent cannot be obtained.

Defines key terms including "gene therapy product" as having capacity to alter or interfere with genes, "genetically modified" as biotechnology-induced alterations not occurring naturally, and "genetic change" as measurable and irreversible alterations to a person's genes.

Applies to foods, cosmetics, and other substances intended for ingestion, introduction into, or application to the human body that induce physiological effects and are made available for retail sale to the general public.